2,991
Views
3
CrossRef citations to date
0
Altmetric
Oncology

Cost-effectiveness of pembrolizumab for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in the United States

, , , &
Pages 954-965 | Received 03 May 2022, Accepted 27 Jun 2022, Published online: 23 Jul 2022